AstraZeneca PLC $AZN Position Boosted by Triad Wealth Partners LLC

Triad Wealth Partners LLC increased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 23.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,418 shares of the company’s stock after purchasing an additional 651 shares during the quarter. Triad Wealth Partners LLC’s holdings in AstraZeneca were worth $239,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC increased its holdings in shares of AstraZeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after buying an additional 2,789 shares in the last quarter. NBC Securities Inc. raised its position in shares of AstraZeneca by 95,925.0% during the first quarter. NBC Securities Inc. now owns 3,841 shares of the company’s stock worth $282,000 after purchasing an additional 3,837 shares during the period. Merit Financial Group LLC raised its position in shares of AstraZeneca by 166.8% during the first quarter. Merit Financial Group LLC now owns 23,583 shares of the company’s stock worth $1,733,000 after purchasing an additional 14,743 shares during the period. Fermata Advisors LLC purchased a new stake in shares of AstraZeneca during the first quarter valued at $293,000. Finally, Thurston Springer Miller Herd & Titak Inc. boosted its position in shares of AstraZeneca by 13.0% in the 1st quarter. Thurston Springer Miller Herd & Titak Inc. now owns 4,602 shares of the company’s stock valued at $338,000 after purchasing an additional 531 shares during the period. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Up 2.0%

AZN opened at $85.31 on Friday. The company has a market capitalization of $264.58 billion, a PE ratio of 32.07, a price-to-earnings-growth ratio of 1.54 and a beta of 0.36. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $85.50. The business has a 50-day moving average of $78.04 and a 200-day moving average of $73.10.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. The business had revenue of $14.46 billion during the quarter, compared to analysts’ expectations of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm’s quarterly revenue was up 16.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.24 EPS. Equities research analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Investors of record on Friday, August 8th were paid a $0.505 dividend. This represents a dividend yield of 200.0%. The ex-dividend date of this dividend was Friday, August 8th. AstraZeneca’s payout ratio is presently 37.97%.

Analyst Upgrades and Downgrades

A number of research firms have commented on AZN. Berenberg Bank set a $97.00 price objective on shares of AstraZeneca in a research note on Wednesday, July 9th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research note on Saturday, September 27th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.